A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.
A-Alpha Bio has raised $14.5M in total funding. The most recent round was Grant. The last funding was announced in May 2024.
A-Alpha Bio's investors include Lux Capital, Madrona, Bill & Melinda Gates Foundation, Perceptive Advisors, Breakout Ventures.
A-Alpha Bio is headquartered in Seattle, United States.
A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.
A-Alpha Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"A-Alpha Bio — Funding & Investors." VCBacked, May 21, 2024, https://www.vcbacked.co/company/a-alpha-bio. Accessed August 13, 2026.
VCBacked. (2024). A-Alpha Bio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/a-alpha-bio
{{cite web |title=A-Alpha Bio — Funding & Investors |url=https://www.vcbacked.co/company/a-alpha-bio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated